With a 7.7% lead, the incoming Christian Democrat Chancellor Friedrich Merz has put the radical right-wing AfD in its place. Before forming a government in Germany, Merz emphasised that Germany wants to strengthen the EU’s self-sufficiency, although the role of biotechnology seems to be of secondary importance to him.
Gene therapy manufacturing: Fuse Vectors secures US$5.2m
Latest NewsFuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.
ECIS TEERZ from Applied BioPhysics
ProductsDunn Labortechnik presents the new TEERZ device from Applied BioPhysics.
Ryvu Therapeutics extends cashflow to consolidate pipeline
Latest NewsKrakow-based oncology specialist Ryvu Therapeutics zoo today announced a strategic reorganisation that will extend Ryvu’s cash runway to H2/2026 to focus on accelerating three ongoing RVU120 clinical programmes, and early pipeline small molecule and ADC assets to key data inflection points.
New German Chancellor wants a strong Europe
Latest NewsWith a 7.7% lead, the incoming Christian Democrat Chancellor Friedrich Merz has put the radical right-wing AfD in its place. Before forming a government in Germany, Merz emphasised that Germany wants to strengthen the EU’s self-sufficiency, although the role of biotechnology seems to be of secondary importance to him.
New non-executive director for Nuclera
AppointmentsCambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
French EG 427 bags €27m in Series B financing
Latest NewsFrench targeted DNA gene therapy specialist EG427 has closed a €27m Series B financing co-led by VC investor Andera Partners and BPI France to initiate Phase I testing of a Herpes Simplex Virus 1 (nrHSV-1) vector that specifically targets type C neurons to suppress dysfunctions of the bladder in people with spinal injury.
Lindis Biotech selects Celonic Group for commercial manufacturing of catumaxomab
Latest NewsLINDIS Biotech GmbH has selected Swiss Celonic Group to manufacture its recently EU-approved malignant ascites treatment catumaxomab for commercial supply.
Cultivated B solves fetal bovine serum problem
Latest NewsGerman-Canadian food tech specialist The Cultivated B reports that it has identified a small molecule that can replace bovine fibroblast growth factor (bFGF) in the production of cell-based meat with a stable, scalable small molecule that results in reproducible quality of sustainably cultured meat.
naturalX secures €100m to fuel the future of consumer health in Europe
Latest NewsThe new fund supports of NaturalX, which has its first closing at €100m, supports proactive healthcare, filling a market gap as consumers take control of their own health journey.
BRAIN Biotech partners with PX Group in microbial gold recycling
Latest NewsGerman BRAIN Biotech AG and the Switzerland’s PX Group will extend its partnership within the framework of the PX Urban Mining Initiative. The extension builds on previous work, which focused on providing a proof of concept for the biological recovery of gold from e-waste and other gold-containing side streams.